Volume 7 Issue 8, Aug 2022

ISSN: 2095-9907 

EISSN: 2059-23635 

2023 impact factor 40.8 

 (Clarivate Analytics, 2024)

Volume 7 Issue 8, Aug 2022:
Article
Inhibition of pancreatic EZH2 restores progenitor insulin in T1D donor
Keith Al-Hasani  ORCID: orcid.org/0000-0001-6109-5603,Ishant Khurana,Lina Mariana,Thomas Loudovaris,Scott Maxwell  ORCID: orcid.org/0000-0002-7801-0714,K. N. Harikrishnan,Jun Okabe  ORCID: orcid.org/0000-0002-7196-0522,Mark E. Cooper &…Assam El-Osta  ORCID: orcid.org/0000-0001-7968-7375 
Type 1 diabetes (T1D) is an autoimmune disease that selectively destroys insulin-producing β-cells in the pancreas. An unmet need in diabetes management, current therapy is focussed on transplantation. While the reprogramming of progenitor cells into functional insulin-producing β-cells has also been proposed this remains controversial and poorly understood. The challenge is determining why default transcriptional suppression is refractory to exocrine reactivation. After the death of a 13-year-old girl with established insulin-dependent T1D, pancreatic cells were harvested in an effort to restore and understand exocrine competence. The pancreas showed classic silencing of β-cell progenitor genes with barely detectable insulin (Ins) transcript. GSK126, a highly selective inhibitor of EZH2 methyltransferase activity influenced H3K27me3 chromatin content and transcriptional control resulting in the expression of core β-cell markers and ductal progenitor genes. GSK126 also reinstated Ins gene expression despite absolute β-cell destruction. These studies show the refractory nature of chromatin characterises exocrine suppression influencing β-cell plasticity. Additional regeneration studies are warranted to determine if the approach of this n-of-1 study generalises to a broader T1D population.